Synergy presents positive new data on plecanatide for constipation

USA-based biopharma group Synergy Pharmaceuticals (Nasdaq: SGYP) has announced new results from the second of two Phase III trials of plecanatide, the company’s first uroguanylin analog, for chronic idiopathic constipation (CIC).

The data was presented at Digestive Disease Week (DDW) in San Diego, USA.

Lead investigator Philip Miner Junior, medical director of the Oklahoma Foundation for Digestive Research, said: “These data show that plecanatide has the potential to address the serious unmet need for people with CIC. Across the two largest trials conducted in CIC, plecanatide showed statistically significant improvement in chronic constipation and abdominal symptoms, such as straining and bloating, with a low rate of side effects.”